These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 17010106)

  • 1. Immunogenicity of synthetic saccharide fragments of Vibrio cholerae O1 (Ogawa and Inaba) bound to Exotoxin A.
    Wade TK; Saksena R; Shiloach J; Kovác P; Wade WF
    FEMS Immunol Med Microbiol; 2006 Nov; 48(2):237-51. PubMed ID: 17010106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transcutaneous immunization with a Vibrio cholerae O1 Ogawa synthetic hexasaccharide conjugate following oral whole-cell cholera vaccination boosts vibriocidal responses and induces protective immunity in mice.
    Tarique AA; Kalsy A; Arifuzzaman M; Rollins SM; Charles RC; Leung DT; Harris JB; Larocque RC; Sheikh A; Bhuiyan MS; Saksena R; Clements JD; Calderwood SB; Qadri F; Kovác P; Ryan ET
    Clin Vaccine Immunol; 2012 Apr; 19(4):594-602. PubMed ID: 22357651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Length of the linker and the interval between immunizations influences the efficacy of Vibrio cholerae O1, Ogawa hexasaccharide neoglycoconjugates.
    Saksena R; Ma X; Wade TK; Kovác P; Wade WF
    FEMS Immunol Med Microbiol; 2006 Jun; 47(1):116-28. PubMed ID: 16706794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthetic fragments of Vibrio cholerae O1 Inaba O-specific polysaccharide bound to a protein carrier are immunogenic in mice but do not induce protective antibodies.
    Meeks MD; Saksena R; Ma X; Wade TK; Taylor RK; Kovác P; Wade WF
    Infect Immun; 2004 Jul; 72(7):4090-101. PubMed ID: 15213154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of saccharide length on the immunogenicity of neoglycoconjugates from synthetic fragments of the O-SP of Vibrio cholerae O1, serotype Ogawa.
    Saksena R; Ma X; Wade TK; Kovác P; Wade WF
    Carbohydr Res; 2005 Oct; 340(14):2256-69. PubMed ID: 16098493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation towards bivalent chemically defined glycoconjugate immunogens prepared from acid-detoxified lipopolysaccharide of Vibrio cholerae O1, serotype Inaba.
    Grandjean C; Boutonnier A; Dassy B; Fournier JM; Mulard LA
    Glycoconj J; 2009 Jan; 26(1):41-55. PubMed ID: 18648931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variable gene family usage of protective and non-protective anti-Vibrio cholerae O1 LPS antibody heavy chains.
    Wade TK; Wade WF
    Microbiol Immunol; 2008 Dec; 52(12):611-20. PubMed ID: 19120975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Construction of novel vaccine strains of Vibrio cholerae co-expressing the Inaba and Ogawa serotype antigens.
    Lebens M; Karlsson SL; Källgård S; Blomquist M; Ekman A; Nygren E; Holmgren J
    Vaccine; 2011 Oct; 29(43):7505-13. PubMed ID: 21807059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of immune responses to the O-specific polysaccharide and lipopolysaccharide of Vibrio cholerae O1 in Bangladeshi adult patients with cholera.
    Johnson RA; Uddin T; Aktar A; Mohasin M; Alam MM; Chowdhury F; Harris JB; LaRocque RC; Bufano MK; Yu Y; Wu-Freeman Y; Leung DT; Sarracino D; Krastins B; Charles RC; Xu P; Kovác P; Calderwood SB; Qadri F; Ryan ET
    Clin Vaccine Immunol; 2012 Nov; 19(11):1712-21. PubMed ID: 22993410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of a novel protective monoclonal antibody that recognizes an epitope common to Vibrio cholerae Ogawa and Inaba serotypes.
    Dharmasena MN; Krebs SJ; Taylor RK
    Microbiology (Reading); 2009 Jul; 155(Pt 7):2353-2364. PubMed ID: 19389772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis, characterization, and some immunological properties of conjugates composed of the detoxified lipopolysaccharide of Vibrio cholerae O1 serotype Inaba bound to cholera toxin.
    Gupta RK; Szu SC; Finkelstein RA; Robbins JB
    Infect Immun; 1992 Aug; 60(8):3201-8. PubMed ID: 1639490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A guide to taming a toxin--recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer.
    Weldon JE; Pastan I
    FEBS J; 2011 Dec; 278(23):4683-700. PubMed ID: 21585657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Cholera Conjugate Vaccine Containing O-specific Polysaccharide (OSP) of V. cholerae O1 Inaba and Recombinant Fragment of Tetanus Toxin Heavy Chain (OSP:rTTHc) Induces Serum, Memory and Lamina Proprial Responses against OSP and Is Protective in Mice.
    Sayeed MA; Bufano MK; Xu P; Eckhoff G; Charles RC; Alam MM; Sultana T; Rashu MR; Berger A; Gonzalez-Escobedo G; Mandlik A; Bhuiyan TR; Leung DT; LaRocque RC; Harris JB; Calderwood SB; Qadri F; Vann WF; Kováč P; Ryan ET
    PLoS Negl Trop Dis; 2015; 9(7):e0003881. PubMed ID: 26154421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity of a killed bivalent (O1 and O139) whole cell oral cholera vaccine, Shanchol, in Haiti.
    Charles RC; Hilaire IJ; Mayo-Smith LM; Teng JE; Jerome JG; Franke MF; Saha A; Yu Y; Kováč P; Calderwood SB; Ryan ET; LaRocque RC; Almazor CP; Qadri F; Ivers LC; Harris JB
    PLoS Negl Trop Dis; 2014 May; 8(5):e2828. PubMed ID: 24786645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine in adults and children in Vellore, South India.
    Raghava Mohan V; Raj S; Dhingra MS; Aloysia D'Cor N; Singh AP; Saluja T; Kim DR; Midde VJ; Kim Y; Vemula S; Narla SK; Sah B; Ali M
    PLoS One; 2019; 14(6):e0218033. PubMed ID: 31211792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conjugating recombinant proteins to Pseudomonas aeruginosa ExoProtein A: a strategy for enhancing immunogenicity of malaria vaccine candidates.
    Qian F; Wu Y; Muratova O; Zhou H; Dobrescu G; Duggan P; Lynn L; Song G; Zhang Y; Reiter K; MacDonald N; Narum DL; Long CA; Miller LH; Saul A; Mullen GE
    Vaccine; 2007 May; 25(20):3923-33. PubMed ID: 17428587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is Pseudomonas aeruginosa exotoxin A a good carrier protein for conjugate vaccines?
    Pier GB
    Hum Vaccin; 2007; 3(2):39-40; author reply 41. PubMed ID: 17268204
    [No Abstract]   [Full Text] [Related]  

  • 18. Transcutaneous immunization with a synthetic hexasaccharide-protein conjugate induces anti-Vibrio cholerae lipopolysaccharide responses in mice.
    Rollenhagen JE; Kalsy A; Saksena R; Sheikh A; Alam MM; Qadri F; Calderwood SB; Kovác P; Ryan ET
    Vaccine; 2009 Aug; 27(36):4917-22. PubMed ID: 19563890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of clinical features and immunological parameters of patients with dehydrating diarrhoea infected with Inaba or Ogawa serotypes of Vibrio cholerae O1.
    Khan AI; Chowdhury F; Harris JB; Larocque RC; Faruque AS; Ryan ET; Calderwood SB; Qadri F
    Scand J Infect Dis; 2010; 42(1):48-56. PubMed ID: 19883159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First characterization of immunogenic conjugates of Vi negative Salmonella Typhi O-specific polysaccharides with rEPA protein for vaccine development.
    Salman M; St Michael F; Ali A; Jabbar A; Cairns C; Hayes AC; Rahman M; Iqbal M; Haque A; Cox AD
    J Immunol Methods; 2017 Nov; 450():27-33. PubMed ID: 28735760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.